| Title |
Spotlight on tavaborole for the treatment of onychomycosis
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2015
|
| DOI | 10.2147/dddt.s81944 |
| Pubmed ID | |
| Authors |
Sphoorthi Jinna, Justin Finch |
| Abstract |
Onychomycosis is a fungal nail plate infection that has been increasing in prevalence. A variety of oral and topical anti-fungal agents are currently available but their use is limited by their adverse effect profile, drug-drug interactions, and limited efficacy. Therefore, there is a great need for newer anti-fungal agents. Tavaborole is one of these newer agents and was approved by the US Food and Drug Administration in July 2014 for the topical treatment of mild to moderate toenail onychomycosis. Tavaborole is a novel, boron-based anti-fungal agent with greater nail plate penetration than its predecessors, due to its smaller molecular weight. It has proven through several Phase II and III trials that it can be a safe and effective topical agent for the treatment of mild to moderate toenail onychomycosis without the need for debridement. In this paper, we review the landscape of topical and systemic treatment of onychomycosis, with particular attention to the pharmacokinetics, safety, and efficacy of topical tavaborole. |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 28% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Bachelor | 5 | 8% |
| Student > Doctoral Student | 4 | 6% |
| Other | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 17 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 17% |
| Medicine and Dentistry | 11 | 17% |
| Chemistry | 7 | 11% |
| Agricultural and Biological Sciences | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Other | 8 | 12% |
| Unknown | 22 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2024.
All research outputs
#3,450,818
of 25,576,275 outputs
Outputs from Drug Design, Development and Therapy
#205
of 2,274 outputs
Outputs of similar age
#46,168
of 295,307 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 103 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,307 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.